Thermo Fisher Scientific Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders elected all director nominees and ratified the auditor, but did not approve executive compensation. The company reported strong financials, highlighted its global reach, and outlined strategic priorities including AI adoption and continued productivity improvements.
-
Positioned as an industry leader, the company targets 7% long-term organic revenue CAGR, driven by innovation, AI adoption, and disciplined capital deployment. Recent acquisitions and a robust commercial engine support share gains, with 2026 guidance of 3%–4% organic growth and 8%–10% EPS growth.
-
Q1 saw 6% revenue and adjusted EPS growth, driven by pharma/biotech strength and the Clario acquisition. Full-year guidance was raised for both revenue and EPS, with strong segment performance and ongoing innovation offsetting inflation and macro headwinds.
-
Strong momentum continues into 2026, with robust growth in pharma, biotech, and bioproduction. AI and innovation are driving efficiency and market share gains, while reshoring and M&A, including the Clario acquisition, position the business for future growth.
-
Delivered strong 2025 results with robust innovation, market share gains, and strategic acquisitions. Outlook for 2026 is positive, with targeted organic growth, margin expansion, and continued investment in AI and sustainability.
Fiscal Year 2025
-
2025 saw strong revenue and EPS growth, driven by robust pharma/biotech performance, innovation, and disciplined capital deployment. 2026 guidance projects 4%–6% revenue growth and 6%–8% EPS growth, with continued share gains and strategic M&A, including the Clario acquisition.
-
Q3 saw 5% revenue and 10% adjusted EPS growth, driven by strong execution and innovation. Full-year 2025 guidance was raised for both revenue and EPS, with robust performance across most segments and continued capital deployment through acquisitions and buybacks.
-
The CEO highlighted robust growth in pharma/biotech and pharma services, ongoing challenges in academic/government and China markets, and a disciplined M&A approach. Innovation and strong customer relationships are driving optimism for 3%-6% organic growth in the next two years, with further acceleration expected.
-
Q2 results exceeded guidance with 3% revenue growth and strong operational execution. Full-year 2025 guidance was raised for both revenue and EPS, with continued cost management and innovation driving performance. Near-term growth is expected to accelerate, supported by robust pharma/biotech demand and strategic acquisitions.
-
The meeting covered director elections, executive compensation, auditor ratification, and a shareholder proposal on special meeting rights. All directors were elected, auditor ratified, but executive compensation and the shareholder proposal failed. Financial performance and strategic growth plans were reviewed.
-
The conference highlighted strong Q1 performance, proactive responses to policy and tariff changes, and a positive long-term outlook for the sector. Key segments like analytical instruments and pharma showed resilience, while capital deployment remains active with ongoing M&A opportunities.
-
Q1 results exceeded expectations with strong execution, $10.36B revenue, and 1% EPS growth. 2025 guidance was updated to reflect $400M tariff and $500M policy headwinds, with mitigation actions expected to offset most impacts by 2026.
-
Sequential market recovery in 2024 set up strong momentum for 2025, with guidance for 3%-4% organic growth and 6%-8% EPS growth. Pharma, biotech, and instruments segments are driving optimism, while recent acquisitions and disciplined cost management support margin expansion and share gains.
-
Differentiated performance and market share gains were achieved in 2024, driven by innovation, operational excellence, and strategic capital deployment. The outlook for 2025 is strong, with new product launches, continued M&A activity, and robust growth expected in key markets.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong revenue and earnings growth, with all end markets contributing and significant share gains. 2025 guidance projects 3%-4% organic revenue growth and 6%-8% adjusted EPS growth, supported by margin expansion and disciplined capital deployment.
-
Market conditions improved steadily in 2023, with consistent share gains and a return to organic growth. Political changes and sector volatility created uncertainty, but a flexible supply chain, disciplined M&A, and strong R&D investment position the company well for 2025.
-
Q3 delivered strong financials with $10.6B revenue and $5.28 adjusted EPS, prompting a raised full-year EPS outlook. Segment performance was mixed, with innovation and commercial wins supporting future growth, while pandemic-related headwinds and muted China demand persisted.
-
Management reaffirmed a long-term organic growth target of 7%-9%, driven by innovation, operational excellence, and disciplined capital deployment. Recent M&A and a robust commercial engine support share gains, while financial guidance calls for mid-teens EPS and free cash flow growth.
-
End markets are gradually improving in 2024, with raised guidance and strong performance in key segments. Bioproduction and clinical research are recovering, while China stimulus and AI adoption are set to drive future growth. Long-term outlook remains positive, with a focus on innovation and strategic M&A.
-
Q2 delivered strong adjusted EPS and margin expansion, with sequential growth across all end markets and robust innovation. 2024 guidance was raised for both revenue and EPS, supported by the Olink acquisition and strong cash flow.